Lung transplantation for late-onset non-infectious chronic pulmonary complications of allogenic hematopoietic stem cell transplant

[1] Gazourian L(2017)Pulmonary clinicopathological correlation after allogeneic hematopoietic stem cell transplantation: an autopsy series Biol Blood Marrow Transplant 23 1767-1772

[2] Spring L(2019)Cause of pleuroparenchymal fibroelastosis following allogeneic hematopoietic stem cell transplantation Respir Investig 57 321-324

[3] Meserve E(2017)Late-onset noninfectious pulmonary complications after allogeneic hematopoietic stem cell transplantation Clin Chest Med 38 249-262

[4] Higo H(2010)Outcome and treatment of late-onset noninfectious pulmonary complications after allogeneic haematopoietic SCT Bone Marrow Transplant 45 1719-1727

[5] Miyahara N(2011)Incidence, risk factors and outcomes of bronchiolitis obliterans after allogeneic stem cell transplantation Int J Hematol 93 375-382

[6] Taniguchi A(2013)Bronchiolitis obliterans after allogeneic hematopoietic SCT: further insight–new perspectives? Bone Marrow Transplant 48 1224-1229

[7] Maeda Y(2019)Managing pulmonary complications in allogeneic hematopoietic stem cell transplantation Expert Rev Respir Med 13 105-119

[8] Kiura K(2015)A consensus document for the selection of lung transplant candidates: 2014–an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation J Heart Lung Transplant 34 1-15

[9] Bergeron A(2015)Survival in sensitized lung transplant recipients with perioperative desensitization Am J Transplant 15 417-426

[10] Ueda K(2020)The impact of first untreated subclinical minimal acute rejection on risk for chronic lung allograft dysfunction or death after lung transplantation Am J Transplant 20 241-249

[1] Gazourian L(2017)Pulmonary clinicopathological correlation after allogeneic hematopoietic stem cell transplantation: an autopsy series Biol Blood Marrow Transplant 23 1767-1772

[2] Spring L(2019)Cause of pleuroparenchymal fibroelastosis following allogeneic hematopoietic stem cell transplantation Respir Investig 57 321-324

[3] Meserve E(2017)Late-onset noninfectious pulmonary complications after allogeneic hematopoietic stem cell transplantation Clin Chest Med 38 249-262

[4] Higo H(2010)Outcome and treatment of late-onset noninfectious pulmonary complications after allogeneic haematopoietic SCT Bone Marrow Transplant 45 1719-1727

[5] Miyahara N(2011)Incidence, risk factors and outcomes of bronchiolitis obliterans after allogeneic stem cell transplantation Int J Hematol 93 375-382

[6] Taniguchi A(2013)Bronchiolitis obliterans after allogeneic hematopoietic SCT: further insight–new perspectives? Bone Marrow Transplant 48 1224-1229

[7] Maeda Y(2019)Managing pulmonary complications in allogeneic hematopoietic stem cell transplantation Expert Rev Respir Med 13 105-119

[8] Kiura K(2015)A consensus document for the selection of lung transplant candidates: 2014–an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation J Heart Lung Transplant 34 1-15

[9] Bergeron A(2015)Survival in sensitized lung transplant recipients with perioperative desensitization Am J Transplant 15 417-426

[10] Ueda K(2020)The impact of first untreated subclinical minimal acute rejection on risk for chronic lung allograft dysfunction or death after lung transplantation Am J Transplant 20 241-249